Contineum Therapeutics, Inc.

CTNM

$17.36

-1.20%

N/A-$0.21

Healthcare

Biotechnology

NASDAQ

Active Trading

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications ...

CEO Profile of CTNM

Carmine Stengone

Contineum Therapeutics, Inc.

Tenure 8yKey-man risk: Medium

Carmine Stengone is a seasoned biopharma executive who has successfully navigated the challenges of transitioning a private company to a public clinical-stage firm. While he has demonstrated strong management and...

Key Risk

•High clinical development failure rate

•Dependency on capital markets for funding

•Volatility in share price linked to trial data

Key Tailwind

•Established clinical-stage pipeline

•Proven access to public capital

•Experienced leadership team

Carmine Stengone

Contineum Therapeutics, Inc. (CTNM) · NASDAQ

Tenure 8 yearsNon-founder CEOKey-man risk: Medium

cstengone

Origin Story

Carmine Stengone transitioned from business leadership roles in the biopharma sector to take the helm at Contineum Therapeutics (formerly Pipeline Therapeutics) in 2018, guiding the company through its clinical evolution and 2024 IPO.

First Break: Prior to joining Contineum in 2018, Carmine Stengone held various executive business development and leadership positions in the biopharmaceutical industry, notably at Amira Pharmaceuticals.

Path to CEO: Stengone joined Contineum Therapeutics (then Pipeline Therapeutics) as President and CEO in October 2018. Over his tenure, he has focused on building a clinical-stage organization specialized in small molecule therapies for neurological and inflammatory diseases, leading the company through its 2024 IPO.

Original Vision: To pioneer novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications.

Carmine Stengone has led Contineum Therapeutics as President and CEO since 2018. He guided the company through a strategic renaming from Pipeline Therapeutics to Contineum in 2023 to better reflect an expanded therapeutic focus. He has been responsible for securing capital, building the executive team, and advancing the company's clinical pipeline through public listing on the NASDAQ in April 2024.

biopharma executiveclinical-stage leader

Investment Take

Key Tailwinds

Established clinical-stage pipeline

Proven access to public capital

Experienced leadership team

Key Risks

High clinical development failure rate

Dependency on capital markets for funding

Volatility in share price linked to trial data

Career History

Carmine Stengone has a long-standing career in biopharmaceutical leadership with an emphasis on corporate strategy and business development.

Contineum Therapeutics

Initiative: President, CEO & Director

Period: 2018–Present

Event: Led the company through a name change, IPO, and clinical development stages.

Outcome: Recent clinical trial failure for lead asset in MS.

Amira Pharmaceuticals

Initiative: Chief Business Officer / Executive

Period: Prior to 2018

Event: Integral in leadership/business strategy.

life sciencesstrategy

Company Performance

The company maintains a focused R&D pipeline but faces challenges following key clinical trial setbacks in 2025.

Revenue: Clinical-stage company with no significant product revenue.

Profitability: Consistent operating losses consistent with clinical-stage biotechnology firms.

Stock: Volatile performance post-IPO, negatively impacted by clinical trial failures in late 2025.

•Successful completion of IPO in April 2024

•Recent positive topline results from chronic pain trials in 2026

•Top drug failure in Multiple Sclerosis (MS) trial (November 2025)

clinical-stagebiotech volatility

Management Ability

Stengone is an experienced operator who has built an executive team with clinical, financial, and development expertise.

Style: Strategic operator

Stengone is credited with building the clinical and R&D organization from an early stage. He emphasizes team composition and has recruited high-level talent to oversee clinical development and biometrics. He maintains a focus on clinical milestones, though the business has faced challenges navigating clinical risks.

team builderstrategic focus

Capital Allocation

Stengone maintains discipline in fundraising but faces high capital intensity typical of clinical-stage biotech.

Focuses on capital-efficient clinical milestone delivery, though net losses are substantial.

IPO on NASDAQ (CTNM): Raised capital to fund clinical trials (April 2024).

Stengone manages cash reserves carefully to balance pipeline advancement with ongoing operating losses. He has successfully tapped public markets to sustain long-term R&D, though capital allocation is inherently high-risk due to the clinical nature of the drug pipeline.

capital marketsfundraising

Fundraising & Financing

Successfully executed an IPO and continues to manage the company's financial runway through public capital raises.

IPO · $110M (targeted): Successful listing in April 2024 providing necessary capital for trials.

Dilution: Typical for a clinical-stage biotech; moderate.

Stengone has shown proficiency in securing financing to support long-term clinical development. His ability to access capital is a key aspect of his leadership, ensuring the company remains liquid while awaiting critical pipeline readouts.

IPOfundraising

Governance & Control

Governance follows typical board structures for a NASDAQ-listed company with standard executive accountability.

Stengone reports to a Board of Directors. The governance structure is typical for a recently public biopharma company, with focus on aligning executive incentives with clinical development outcomes.

corporate governance

Health & Succession

No public concerns or specific disclosures regarding health or succession plans identified.

Health Status: No public concerns

Key-man Risk: Medium

Typical for an SME biotech; high dependency on current leadership.

key-man risk

R&D & Tech Vision

The CEO's vision hinges on small molecule therapies for complex NI&I diseases, with a focus on clinically validated targets.

High, as the company is entirely R&D-focused.

Neuroscience, Inflammation, and Immunology pipeline: Ongoing, mixed clinical results.

Highly dependent on clinical trial results; high risk.

•Identifying early potential in specific NI&I indications prior to IPO.

Stengone has prioritized a pipeline that targets validated biological pathways. His focus has been on scaling the team's ability to execute complex clinical trials, which is central to his long-term product vision for the company.

innovationr&d

Talent Recruitment

Stengone has demonstrated an ability to attract seasoned biopharma executives to lead the R&D and clinical functions.

Timothy Watkins, M.D., M.Sc. (CMO): Strengthened clinical development and pulmonology expertise.

Strong clinical and industry experience.

Retention: Strong.

Stengone focuses on hiring key scientific and clinical leadership to oversee the pipeline. The team composition appears professional and experienced, suggesting he prioritizes talent acquisition as a core management duty.

talent magnetexecutive team

Strengths

His defining strength is his ability to lead organizational transition and secure capital for clinical development.

Capital Markets: Successfully led the company to an IPO in 2024, ensuring liquidity.

Team Building: Hiring of key executive leadership such as a new CMO in 2025.

fundraisingorganizational leader

Weaknesses & Failures

The most significant challenge has been navigating the high-risk clinical development process, evidenced by trial failures.

Clinical Risk

High volatility due to clinical trial outcomes.

Example: Failure of lead MS drug trial in late 2025.

clinical risk

Marketing & Brand

Brand perception centers on scientific innovation in the NI&I space, though it remains relatively niche to the investment and scientific community.

Shifted perception from 'Pipeline' to 'Contineum' to signal a more mature, focused clinical organization.

Stengone has worked to position Contineum as a leader in neuroscience, inflammation, and immunology. Public communications are focused on scientific progress and clinical trial milestones. The brand suffered some damage following public disclosures of clinical trial failures in late 2025.

biotech brandingscientific positioning

PR & Communication

Stengone is the primary public face of the company, consistently communicating milestones and addressing setbacks with professional transparency.

Media Reputation: positive

Event: Clinical failure in MS trial (2025)

Handling: Transparent disclosure and re-focusing on other clinical catalysts.

Stengone effectively handles earnings calls and investor interactions. He maintains a professional and disciplined tone, particularly when communicating both positive clinical updates and necessary bad news regarding trial outcomes.

investor relationstransparency

Supply Chain of CTNM

Upstream / Downstream / Proxies

Upstream

Third-Party CMO (API Manufacturing)Third-Party CMO (Drug Product Manufacturing)Third-Party CRO (Clinical Trial Management)Preclinical CRO PartnersSpecialty Chemical / Raw Material SuppliersSpecialty Chemical Distributors (e.g., Sigma-Aldrich/Merck, Thermo Fisher)NYSE:MRK Laboratory Equipment SuppliersNYSE:TMO

Downstream

Johnson & Johnson (Janssen Pharmaceutica NV)NYSE:JNJNo commercial customers (pre-revenue, clinical-stage)No commercial distributors (pre-revenue, clinical-stage)

Proxies

Johnson & JohnsonNYSE:JNJVersant VenturesUnconfirmedReata Pharmaceuticals / BiogenUnconfirmedPliant TherapeuticsNASDAQ:PLRX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer